P3246
Pipamperone dihydrochloride
~99% (HPLC), dopamine receptor antagonist, powder
Synonym(s):
1′-[4-(4-Fluorophenyl)-4-oxobutyl]-[1,4′-bipiperidine]-4′-carboxamide dihydrochloride, R4050
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H30N3O2F · 2HCl
CAS Number:
Molecular Weight:
448.40
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
219-507-5
MDL number:
Product Name
Pipamperone dihydrochloride, ~99% (HPLC), powder
InChI
1S/C21H30FN3O2.2ClH/c22-18-8-6-17(7-9-18)19(26)5-4-12-24-15-10-21(11-16-24,20(23)27)25-13-2-1-3-14-25;;/h6-9H,1-5,10-16H2,(H2,23,27);2*1H
InChI key
BMXXSXQVMCXGJM-UHFFFAOYSA-N
SMILES string
Cl[H].Cl[H].NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N3CCCCC3
assay
~99% (HPLC)
form
powder
color
white
solubility
H2O: >2.0 mg/mL
originator
Johnson & Johnson
Quality Level
Related Categories
Application
Pipamperone dihydrochloride may be used:
- as an internal standard in liquid chromatography with coulometric detection
- as an antipsychotic drugs to test its interaction with human ether-a-go-go-related gene (hERG) channel
- as an internal standard to spike human colostrum samples for reversed phase liquid chromatography- ultraviolet (LC-UV) analysis
Biochem/physiol Actions
D2 dopamine receptor antagonist; 5-HT2 serotonin receptor antagonist; antipsychotic.
Pipamperone, a butyrophenone derivative is a pharmacological chaperone and is a membrane-permeable dopamine receptor D4 (DRD4) antagonist. The affinity of pipamperone is higher for DRD4 and 5-hydroxytryptamine 2A receptor (5-HT2A) in comparison with DRD2. It may be useful therapeutic in treating behavioral disorders and psychomotor agitation symptoms.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Schwaninger et al.
Clinical neuropharmacology, 21(6), 344-346 (1998-12-09)
Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred.
Maria Addolorata Saracino et al.
Talanta, 81(4-5), 1547-1553 (2010-05-06)
A new analytical method, based on the use of liquid chromatography with coulometric detection, has been developed and applied to quantify risperidone and its main active metabolite 9-hydroxyrisperidone in human plasma and saliva. The analytes were separated on a reversed
K Nisijima et al.
Brain research, 890(1), 23-31 (2001-02-13)
The serotonin (5-HT) syndrome is the most serious side effect of antidepressants, and it often necessitates pharmacotherapy. In the present study, the efficacy of several drugs was evaluated in an animal model of the 5-HT syndrome. When 2 mg/kg of
J E Belgaied et al.
Journal of pharmaceutical and biomedical analysis, 30(4), 1417-1423 (2002-11-01)
The electrochemical reduction of pipamperone has been carried out in aqueous solution in KNO(3) (0.1 mol l(-1)) by differential-pulse polarography (DPP). Pipamperone exhibits a well-defined irreversible reduction peak at -1.3 V/ref. The influence of pH on the reduction of pipamperone
Hypothermia in a patient with Alzheimer's disease receiving a combination therapy with risperidone and pipamperone.
Daniel Kamp et al.
Therapeutic advances in psychopharmacology, 6(1), 55-57 (2016-02-26)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service